BTK inhibitors

Bruton Tyrosine Kinase (BTK) inhibitors inhibit the enzyme BTK, which plays a crucial role in oncogenic signaling and interactions with tumor microenvironment critical for proliferation, and survival of malignant B cells. Examples of BTK inhibitors include ibrutinib, zanubrutinib, and acalabrutinib.

All Therapeutics

BTK inhibitors

• Acalabrutinib
• Ibrutinib

Articles of Interest

1. Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19

Published Nov 5, 2020

2. The impact of targeted treatment and immunotherapies on the role of hematopoietic stem cell transplantation in the treatment of blood cancers

Published Apr 9, 2020

3. Efficacy and safety of ibrutinib in RRMM

Published Mar 5, 2018

Filter by content:

• Types
• Therapeutics
• Congresses
• Trials
• Expert Opinions
• Educational Resources